Brief: Medivir Enters Into Licensing Agreement With IGM Biosciences For Birinapant
12/01/2021 03:26
Jan 11 (Reuters) - Medivir AB MVIRb.ST :
* ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH IGM
BIOSCIENCES
FOR BIRINAPANT
* TO RECEIVE AN UPFRONT PAYMENT, AS WELL AS MILESTONE
PAYMENTS AND
ROYALTIES
* TO RECEIVE MILESTONE PAYMENTS UP TO A TOTAL OF
APPROXIMATELY USD
350 MILLION, PLUS TIERED ROYALTIES UP TO MID-TEENS ON NET SALES
* TO RECEIVE UPFRONT PAYMENT $1 MILLION UPON SIGNING,
FOLLOWED BY
ADDITIONAL $1.5 MILLION WHEN BIRINAPANT INCLUDED BY IGM IN
CLINICAL PHASE I STUDIES
* IGM TO DEVELOP BIRINAPANT IN COMBINATION WITH IGM-8444 FOR
TREATMENT OF SOLID TUMORS
Source text for Eikon: ID:nPn9wz1Zna
Further company coverage: MVIRb.ST
((Reuters.Briefs@thomsonreuters.com;))